by Luke Pettit | Jul 30, 2026 | US & International
As a reminder, this case addresses how the Hatch-Waxman act “carve-out” provisions (which has led to the emergence of “skinny labels”) interacts with US law on induced patent infringement. This case is the first time the US Supreme Court has had the opportunity to...
by Alyson Lam | Jul 28, 2026 | US & International
On 16–17 June 2026, the Court heard Otsuka’s appeal in Otsuka Pharmaceutical Co Ltd v Sun Pharma ANZ Pty Ltd. The appeal challenges the Full Federal Court’s finding that formulation patents are not eligible for patent term extensions (PTEs). The decision, expected in...
by Sean Hutchinson | Jul 23, 2026 | UK
In 2017, the UK Supreme Court issued a landmark judgment setting out how it believed the UK should apply the so-called “doctrine of equivalents” when deciding on infringement of a patent. This judgment was handed down in the case of Actavis v Eli Lilly and the test...
by Alyson Lam | Jul 14, 2026 | US & International
Overview Broad antibody claims have faced a difficult path in the US since Amgen v Sanofi, particularly where the claim covers a large functional genus. The Federal Circuit’s decision in Teva v Eli Lilly is therefore interesting because the court drew an important...
by Sean Hughes | Jun 22, 2026 | EPO
Admissibility: Should the Enlarged Board Answer at All? The first question in G 1/26 is procedural. The referring Board asks whether a referral is “required” under Article 112(1) EPC where the legal issue arises in the pending case but the Board has not...
Recent Comments